Last reviewed · How we verify
Placebo fluticasone
Placebo fluticasone is a Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently FDA-approved for Control arm in clinical trials evaluating fluticasone efficacy in allergic rhinitis, asthma, or other respiratory conditions. Also known as: Placebo Flovent® Diskus®, Advair.
Placebo fluticasone has no active pharmacological effect, as it is an inert control formulation used in clinical trials.
Placebo fluticasone is a nasal spray used in clinical trials to compare its safety and efficacy with other treatments for conditions such as seasonal allergic rhinitis, asthma, and perennial allergic rhinitis. It is a component of a study comparing two steroid treatments for the relief of symptoms of seasonal allergic rhinitis, as identified by ClinicalTrials.gov.
At a glance
| Generic name | Placebo fluticasone |
|---|---|
| Also known as | Placebo Flovent® Diskus®, Advair |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Biologic |
| Therapeutic area | Respiratory/Allergy |
| Phase | FDA-approved |
Mechanism of action
Placebo fluticasone is a non-active comparator used in randomized controlled trials to evaluate the efficacy of active fluticasone formulations. It contains no active pharmaceutical ingredient and serves as a control to distinguish true drug effects from placebo response. Any observed effects in the placebo group are attributable to placebo response rather than pharmacological action.
Approved indications
- Control arm in clinical trials evaluating fluticasone efficacy in allergic rhinitis, asthma, or other respiratory conditions
Common side effects
Key clinical trials
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps (PHASE3)
- A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma (PHASE3)
- Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) (PHASE2)
- Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma (PHASE3)
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma (PHASE4)
- As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo fluticasone CI brief — competitive landscape report
- Placebo fluticasone updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about Placebo fluticasone
What is Placebo fluticasone?
How does Placebo fluticasone work?
What is Placebo fluticasone used for?
Who makes Placebo fluticasone?
Is Placebo fluticasone also known as anything else?
What development phase is Placebo fluticasone in?
Related
- Manufacturer: National Institute of Allergy and Infectious Diseases (NIAID) — full pipeline
- Therapeutic area: All drugs in Respiratory/Allergy
- Indication: Drugs for Control arm in clinical trials evaluating fluticasone efficacy in allergic rhinitis, asthma, or other respiratory conditions
- Also known as: Placebo Flovent® Diskus®, Advair
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing